Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in Subjects With CML
Public ClinicalTrials.gov record NCT00123487. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized Two-Arm, Multicenter, Open-Label Phase III Study of BMS-354825 Administered Orally at a Dose of 70 mg Twice Daily or 140 mg Once Daily in Subjects With Chronic Myeloid Leukemia in Accelerated Phase or in Myeloid or Lymphoid Blast Phase or With Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Who Are Resistant or Intolerant to Imatinib Mesylate (Gleevec)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a phase III study of BMS-354825 in subjects with chronic myelogenous leukemia in accelerated phase, or in myeloid or lymphoid blast phase or with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia who are resistant or intolerant to imatinib mesylate (Gleevec).
Study identification
- NCT ID
- NCT00123487
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 638 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 2005 (Type not available)
- Primary completion
- Nov 2006 (Actual)
- Completion
- Jun 2013 (Actual)
- Last update posted
- Nov 3, 2014
2005 – 2013
United States locations
- U.S. sites
- 26
- U.S. states
- 22
- U.S. cities
- 24
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University Of Alabama At Birmingham | Birmingham | Alabama | 35294 | — |
| Loma Linda University Cancer Center | Loma Linda | California | 92354 | — |
| Ucla Dept. Of Medicine | Los Angeles | California | 90095 | — |
| Washington Cancer Institute At Washington Hospital Center | Washington D.C. | District of Columbia | 20010 | — |
| University Of Miami | Miami | Florida | 33136 | — |
| Emory University School Of Medicine | Atlanta | Georgia | 30322 | — |
| Northwestern University | Chicago | Illinois | 60611 | — |
| The University Of Chicago | Chicago | Illinois | 60637-1463 | — |
| Indiana University Cancer Center | Indianapolis | Indiana | 46202 | — |
| University Of Kentucky | Lexington | Kentucky | 40536-0098 | — |
| University Of Maryland | Baltimore | Maryland | 21201-1595 | — |
| Dana Faber Cancer Institute | Boston | Massachusetts | 02115 | — |
| Karmanos Cancer Center | Detroit | Michigan | 48201 | — |
| Washington University School Of Medicine | St Louis | Missouri | 63110-1093 | — |
| Nebraska Methodist Hospital | Omaha | Nebraska | 68114 | — |
| Devetten, Marcel | Omaha | Nebraska | 68198-7680 | — |
| The Cancer Center At Hackensack University Medical Center | Hackensack | New Jersey | 07601 | — |
| The Cancer Institute Of New Jersey | New Brunswick | New Jersey | 08903 | — |
| New York Presbyterian Hospital | New York | New York | 10021 | — |
| The University Of North Carolina At Chapel Hill | Chapel Hill | North Carolina | 27599-7305 | — |
| Cleveland Clinic Foundation | Cleveland | Ohio | 44195 | — |
| Oregon Health & Sci Univ | Portland | Oregon | 97239 | — |
| Western Pennsylvania Cancer Institute | Pittsburgh | Pennsylvania | 15224 | — |
| Sarah Cannon Research Institute | Nashville | Tennessee | 37203 | — |
| The University Of Texas Md Anderson Cancer Center | Houston | Texas | 77030 | — |
| Seattle Cancer Care Alliance | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 93 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00123487, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 3, 2014 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00123487 live on ClinicalTrials.gov.